Adrian Dirk
Family Medicine · Gatesville, TXNPI 1841553153
Payments from drug & device makers
Across 299 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$894
- AbbVie$847
- Pfizer$634
- Astellas Pharma US Inc$255
- Supernus Pharmaceuticals, Inc.$254
- Lilly USA, LLC$253
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,745100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 65 | $894 |
| AbbVie(2 entities) | 41 | $847 |
| Pfizer | 52 | $634 |
| Astellas Pharma US Inc | 10 | $255 |
| Supernus Pharmaceuticals, Inc. | 11 | $254 |
| Lilly USA, LLC | 18 | $253 |
| Sanofi-aventis U.S. LLC | 14 | $215 |
| GSK | 16 | $194 |
| Sumitomo Pharma America, Inc. | 6 | $128 |
| AstraZeneca | 6 | $115 |
| Merck | 8 | $112 |
| Si-bone, Inc. | 1 | $75 |
| Amgen | 5 | $75 |
| Biohaven Pharmaceuticals, Inc. | 4 | $64 |
| Novartis | 4 | $58 |
| Boehringer Ingelheim | 3 | $54 |
| Exact Sciences | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $51 |
| Xeris Pharmaceuticals, Inc. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 3 | $48 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $31 |
| Johnson & Johnson | 2 | $31 |
| Dexcom, Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Tris Pharma Inc | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$107
How this compares
$4,745 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 208 | $124,115 |
| OzempicSemaglutide | 101 | $99,091 |
| MounjaroTirzepatide | 86 | $91,002 |
| XareltoRivaroxaban | 83 | $51,039 |
| TrulicityDulaglutide | 46 | $46,495 |
| Invega SustennaPaliperidone Palmitate | 11 | $38,465 |
| JardianceEmpagliflozin | 38 | $36,778 |
| RexultiBrexpiprazole | 13 | $18,280 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $15,536 |
| JanuviaSitagliptin Phosphate | 12 | $15,282 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $13,684 |
| LinzessLinaclotide | 12 | $12,953 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 57 | $11,054 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $10,328 |
| MyrbetriqMirabegron | 31 | $8,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $253 | $137,496132 claims |
| PfizerEliquis, Premarin | $634 | $130,818229 claims |
| Novo NordiskOzempic | $894 | $99,091101 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $31 | $89,50494 claims |
| Boehringer IngelheimJardiance, Tradjenta | $54 | $41,95849 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $194 | $29,22038 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $49 | $18,28013 claims |
| MerckJanuvia | $112 | $15,28212 claims |
| AbbVieLinzess | $847 | $12,95312 claims |
| Astellas Pharma US IncMyrbetriq | $255 | $8,62631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Gatesville
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.